JP2009530279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530279A5 JP2009530279A5 JP2009500424A JP2009500424A JP2009530279A5 JP 2009530279 A5 JP2009530279 A5 JP 2009530279A5 JP 2009500424 A JP2009500424 A JP 2009500424A JP 2009500424 A JP2009500424 A JP 2009500424A JP 2009530279 A5 JP2009530279 A5 JP 2009530279A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- polymorph
- solvent
- compound
- phenylacetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002904 solvent Substances 0.000 claims 21
- -1 4-Chloro-3-methyl-5-isoxazolyl Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 159000000000 sodium salts Chemical class 0.000 claims 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 9
- BWJZHYWAXLWLTB-UHFFFAOYSA-N thiophene-3-sulfonamide Chemical compound NS(=O)(=O)C=1C=CSC=1 BWJZHYWAXLWLTB-UHFFFAOYSA-N 0.000 claims 9
- 239000012047 saturated solution Substances 0.000 claims 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 239000012296 anti-solvent Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000001237 Raman spectrum Methods 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 239000002244 precipitate Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 3
- 229940011051 isopropyl acetate Drugs 0.000 claims 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims 1
- 208000019255 Menstrual disease Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 230000008717 functional decline Effects 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78186106P | 2006-03-13 | 2006-03-13 | |
| PCT/US2007/006277 WO2007106467A2 (en) | 2006-03-13 | 2007-03-12 | Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl)2-[2-methyl-4,5-(methylenedioxy) phenylacetyl]thiophene-3-sulfonamide, sodium salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530279A JP2009530279A (ja) | 2009-08-27 |
| JP2009530279A5 true JP2009530279A5 (https=) | 2010-04-30 |
Family
ID=38335653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500424A Withdrawn JP2009530279A (ja) | 2006-03-13 | 2007-03-12 | Ｎ−（４−クロロ−３−メチル−５−イソキサゾリル）２−［２−メチル−４，５−（メチレンジオキシ）フェニルアセチル］チオフェン−３−スルホンアミド、ナトリウム塩の多形 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090104265A1 (https=) |
| EP (1) | EP1996582A2 (https=) |
| JP (1) | JP2009530279A (https=) |
| KR (1) | KR101019264B1 (https=) |
| CN (1) | CN101443329A (https=) |
| AU (1) | AU2007225206B2 (https=) |
| BR (1) | BRPI0709384A2 (https=) |
| CA (1) | CA2644134A1 (https=) |
| IL (1) | IL193682A0 (https=) |
| MX (1) | MX2008011843A (https=) |
| NZ (1) | NZ570943A (https=) |
| RU (1) | RU2412941C2 (https=) |
| WO (1) | WO2007106467A2 (https=) |
| ZA (1) | ZA200807302B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090004268A1 (en) * | 2007-03-13 | 2009-01-01 | Given Bruce D | Methods and Compositions for Treatment of an Interstitial Lung Disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5793705A (en) * | 1996-09-18 | 1998-08-11 | International Business Machines Corporation | Ultrasonic liquid level gauge for tanks subject to movement and vibration |
| US5783705A (en) * | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP4097893B2 (ja) * | 2000-12-05 | 2008-06-11 | 株式会社エフ・ティ・エスコーポレーション | 対向ターゲット式スパッタ方法及び導電性膜の形成方法 |
| AU2003233946A1 (en) * | 2002-03-15 | 2003-09-29 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
-
2007
- 2007-03-12 EP EP07752939A patent/EP1996582A2/en not_active Withdrawn
- 2007-03-12 KR KR1020087022438A patent/KR101019264B1/ko not_active Expired - Fee Related
- 2007-03-12 RU RU2008136316/04A patent/RU2412941C2/ru not_active IP Right Cessation
- 2007-03-12 JP JP2009500424A patent/JP2009530279A/ja not_active Withdrawn
- 2007-03-12 US US11/717,498 patent/US20090104265A1/en not_active Abandoned
- 2007-03-12 AU AU2007225206A patent/AU2007225206B2/en not_active Ceased
- 2007-03-12 NZ NZ570943A patent/NZ570943A/en not_active IP Right Cessation
- 2007-03-12 MX MX2008011843A patent/MX2008011843A/es not_active Application Discontinuation
- 2007-03-12 BR BRPI0709384-5A patent/BRPI0709384A2/pt not_active IP Right Cessation
- 2007-03-12 WO PCT/US2007/006277 patent/WO2007106467A2/en not_active Ceased
- 2007-03-12 CN CNA2007800174618A patent/CN101443329A/zh active Pending
- 2007-03-12 CA CA002644134A patent/CA2644134A1/en not_active Abandoned
-
2008
- 2008-08-25 IL IL193682A patent/IL193682A0/en unknown
- 2008-08-25 ZA ZA200807302A patent/ZA200807302B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025176008A5 (https=) | ||
| CN101573368B (zh) | 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 | |
| JP4585610B2 (ja) | 治療用化合物のトシル酸塩およびその医薬組成物 | |
| CN102099355B (zh) | 苯基和苯并二氧杂环己烯基取代的吲唑衍生物 | |
| JP2022068321A5 (https=) | ||
| JP7621289B2 (ja) | ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用 | |
| JP2021504310A5 (https=) | ||
| CN109503625A (zh) | 一种多环吡啶酮化合物及其药物组合和用途 | |
| CN102827153B (zh) | 阿齐沙坦的晶型及其制备方法 | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2019515024A (ja) | ボルチオキセチンのパモ酸塩及びその結晶形 | |
| JP5160219B2 (ja) | テルミサルタンの製造方法 | |
| CN109937200B (zh) | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 | |
| JP2004501116A (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| JP2024095561A5 (https=) | ||
| JP2025148397A5 (https=) | ||
| WO2016034103A1 (zh) | 取代的四氢噻吩并吡啶衍生物及其应用 | |
| JP2009530279A5 (https=) | ||
| CN109071551B (zh) | 一种三氟甲基取代的吡喃衍生物的制备方法 | |
| CN104628708A (zh) | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 | |
| RU2008136316A (ru) | Полиморфы натриевой соли n-(4-хлор-3метил-5-изоксазолил)-2{2-метил-4, 5-(метелендиокси)фенилацетил}тиофен-3-сульфонамида | |
| CN102731488A (zh) | 苯并咪唑类衍生物、及其制法和药物组合物与用途 | |
| CN108558760A (zh) | 一类芳香酰胺化合物及其制备方法和用途 | |
| CN105061352A (zh) | 芳基哌嗪衍生物ⅲ及其盐、制备方法和用途 | |
| CN104072477B (zh) | 伊马替尼的精制方法 |